1. Home
  2. APLT vs SMR Comparison

APLT vs SMR Comparison

Compare APLT & SMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • SMR
  • Stock Information
  • Founded
  • APLT 2016
  • SMR 2007
  • Country
  • APLT United States
  • SMR United States
  • Employees
  • APLT N/A
  • SMR N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • SMR Electrical Products
  • Sector
  • APLT Health Care
  • SMR Industrials
  • Exchange
  • APLT Nasdaq
  • SMR Nasdaq
  • Market Cap
  • APLT 971.6M
  • SMR 960.6M
  • IPO Year
  • APLT 2019
  • SMR N/A
  • Fundamental
  • Price
  • APLT $9.13
  • SMR $18.66
  • Analyst Decision
  • APLT Strong Buy
  • SMR Buy
  • Analyst Count
  • APLT 5
  • SMR 5
  • Target Price
  • APLT $12.50
  • SMR $11.50
  • AVG Volume (30 Days)
  • APLT 1.5M
  • SMR 14.3M
  • Earning Date
  • APLT 11-15-2024
  • SMR 11-07-2024
  • Dividend Yield
  • APLT N/A
  • SMR N/A
  • EPS Growth
  • APLT N/A
  • SMR N/A
  • EPS
  • APLT N/A
  • SMR N/A
  • Revenue
  • APLT N/A
  • SMR $13,856,000.00
  • Revenue This Year
  • APLT N/A
  • SMR N/A
  • Revenue Next Year
  • APLT $3,358.27
  • SMR $181.20
  • P/E Ratio
  • APLT N/A
  • SMR N/A
  • Revenue Growth
  • APLT N/A
  • SMR N/A
  • 52 Week Low
  • APLT $1.79
  • SMR $1.81
  • 52 Week High
  • APLT $9.51
  • SMR $22.75
  • Technical
  • Relative Strength Index (RSI)
  • APLT 60.69
  • SMR 58.97
  • Support Level
  • APLT $8.38
  • SMR $17.46
  • Resistance Level
  • APLT $9.51
  • SMR $22.75
  • Average True Range (ATR)
  • APLT 0.51
  • SMR 2.01
  • MACD
  • APLT -0.04
  • SMR -0.22
  • Stochastic Oscillator
  • APLT 67.54
  • SMR 32.32

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About SMR NuScale Power Corporation

NuScale Power Corp is engaged in the development of a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, hydrogen production, and other process heat applications.

Share on Social Networks: